Yunfeng Capital and Gaorong Capital Lead USD200m Series B for Sironax

Yunfeng Capital and Gaorong Capital led a USD200m Series B for Sironax, a China-based clinical-stage biotech with a focus on the treatment of age-related degenerative disease, with participation from MSA Capital, a subsidiary of Abu Dhabi Investment Authority (ADIA), CBC Group, Long River Investments, LSV Capital, Superstring Capital and Future… Read More



(default archive template)